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doi:10.1016/j.ejvs.2010.12.016Abstract Objective: The Dutch Bypass and Oral anticoagulants or Aspirin (BOA) Study
demonstrated that in patients with peripheral arterial disease after bypass surgery oral anti-
coagulants were more effective in preventing venous graft occlusions than aspirin, while
aspirin was more effective in non-venous grafts. We evaluated if this finding was implemented
in the clinical practice of former BOA participants by reconstructing a 10-year overview of
their applied various drug treatments including anti-hypertensive and lipid-lowering drugs.
Methods: In 482 patients from six centers that contributed most patients anti-thrombotic,
anti-hypertensive, and lipid-lowering drug use was recorded at baseline (nZ 478), retrospec-
tively up to two years after BOA (n Z 388), and prospectively for patients still alive between
2005 and 2009 (n Z 209).
Results: At baseline, 54% of patients received anti-thrombotics which increased to 96% at
follow-up. At baseline 15% of patients were treated with lipid-lowering drugs and 49% with
anti-hypertensives. This increased over time to 65% and 76%, respectively.
Conclusion: After the BOA Study its recommendations were applied marginally. Despite
improvements over time, current lipid-lowering and anti-hypertensive drug use remained
suboptimal. Our trend analyses, however, should be interpreted with caution, because drug
use and compliance in survivors might be better than average.
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806 E.S. van Hattum et al.Peripheral bypass surgery is a commonly accepted treat-
ment for disabling intermittent claudication and critical
limb ischaemia (CLI), a grave condition of chronic
peripheral arterial disease (PAD).1 Unfortunately, the risk
of graft failure is high.2 Anti-thrombotic treatment has
proven highly beneficial to prevent graft occlusion.3 The
Dutch Bypass and Oral anticoagulants or Aspirin (BOA)
Study found oral anticoagulants to be more effective in
preventing venous graft occlusion, while aspirin was more
effective in non-venous grafts.4 Before the Dutch BOA
Study, a survey was performed among Dutch vascular
surgeons to inquire after their preference in anti-throm-
botic drug prescription for patients after infrainguinal
bypass surgery.5 After the Dutch BOA Study, the survey
was repeated and showed an increased preference for
aspirin for all graft types. Notably, this preference had
increased the most for patients with non-venous grafts,
which was supported by the results of the Dutch BOA
Study.6 However, against BOA recommendations, the
preference for oral anticoagulants after venous bypass
surgery had decreased. The decrease in oral anticoagu-
lant prescription might be explained by its concomitant
higher bleeding risk than aspirin and the inherent diffi-
culties of monitoring the international normalised ratio
(INR) with frequent dose adjustments. Even so, surveys
only provide subjective measurements rather than actual
individual drug use. To evaluate the implementation of
BOA recommendations in clinical practice, data on anti-
thrombotic treatment were collected during the long-
term follow-up of patients, who had participated in the
Dutch BOA Study.
Atherosclerosis is a systemic disease.7 After peripheral
bypass surgery, patients not only are at risk of graft occlu-
sion, but also have an increased risk ofmyocardial infarction,
stroke or vascular death. Anti-thrombotic treatment, blood
pressure control and low serum lipid levels reduce vascular
morbidity andmortality rates inPADpatients.810 Therefore,
we recorded anti-hypertensive and lipid-lowering drug use as
well.
Our overall aim was to describe a 10-year overview of
changes in the applied secondary medical prevention in
patients with PAD derived from the Dutch BOA Study, who
were followed up from before they underwent infrainguinal
bypass surgery until long thereafter.Figure 1 Data collection. Before BOA: time period up to four
1995; After BOA: time period up to two years after close-out of the
2009.Methods
Study population
Between 1995 and 1998, the Dutch BOA Study included 2650
patients with PAD after infrainguinal bypass surgery from 77
medical centres throughout the Netherlands.4 All PAD
patients, who required an infrainguinal bypass surgery,
were eligible for inclusion. Exclusion criteria were contra-
indication or absolute indication for one of the trial medi-
cations, markedly reduced life expectancy, myocardial
infarction or stroke 1 month prior to operation, abnormal-
ities of blood platelets or erythrocytes, anaemia, inability
to comply with the protocol or inability to give informed
consent. After bypass surgery, patients were randomised to
oral anticoagulants (phenprocoumon or acenocoumarol)
with a target INR range of 3.0e4.5 or aspirin (100 mg car-
basalate calcium once daily). Between treatment groups,
the efficacy of the two anti-thrombotics for the prevention
of infrainguinal bypass occlusion, amputation and other
vascular events was compared. Details of the Dutch BOA
Study have been published elsewhere.4 Between 2005 and
2009, a retrospective follow-up of the Dutch BOA Study was
performed in 482 patients from the six centres that
contributed the most patients.
Data collection
The patient characteristics were registered prospectively
at randomisation of the Dutch BOA Study.4 Anti-thrombotic,
anti-hypertensive and lipid-lowering drug use was recorded
at study baseline, retrospectively up to 2 years after BOA
close-out, and prospectively in patients still alive between
2005 and 2009 (Fig. 1). In cases where medication was not
documented at the first patient visit or at admission prior to
the index admission, retrospective patient record analysis
was performed. In addition to drug use, data on outcome
events were registered as well from the last patient visit of
the Dutch BOA Study in April 1998 until August 2009.
Registered outcome events were bypass occlusion of the
treated leg, non-fatal myocardial infarction, non-fatal
ischaemic stroke, major amputation and death. The defi-
nition of each outcome event has been published in full
detail elsewhere.4 Each recorded outcome event wasyears before the index admission of the Dutch BOA Study in
Dutch BOA Study in 1998; BOA FU: time period from 2005 until
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medical specialists from the University Medical Center
Utrecht, the Netherlands.
Data collection occurred in a stepwise manner. First, the
attending vascular surgeon was asked for the patient’s drug
use and experienced outcome events. Then, the general
practitioner or pharmacist was contacted. When at both
sources, no sufficient data could be obtained, the patient
was contacted. In case the patient could not be reached,
the municipality office was approached to inquire if the
patient had moved and to receive the patient’s current
home address. In case the patient had died, his/her rela-
tives or acquaintances were approached for follow-up data.
If none responded, the registry office was contacted to
determine if the patient had died.
Ethical aspects
Informed consent was obtained from all patients and
participants at randomisation of the Dutch BOA Study and
again from patients alive at long-term follow-up. Data
collection of patients, who had died at time of our
approach, was allowed by Dutch law in the medical treat-
ment agreement (WGBO art. 458). The authors had full
access to the data, take responsibility for its integrity and
agreed to the article as written.
Statistic analysis
Dichotomous data were presented as numbers and
percentages, and continuous data as means with standard
deviations (SDs). Results were presented graphically as
histograms.
Results
Study population and data collection
The Dutch BOA Follow-up Study comprised 482 patients with
a mean age of 69 years at randomisation (Table 1). More
than half of the patients were male and smoked. Other
vascular risk factors, such as hypertension, diabetes melli-
tus and hyperlipidaemia were present in approximately
a quarter of patients. Nearly a fifth had a history of angina
pectoris, myocardial infarction or stroke. About half had CLI
and a vascular intervention before BOA inclusion. Most
procedures consisted of venous femoro-popliteal bypasses.
After retrospective completion of the data in a mean
period of 4 months (range, 0e61 months), data on drug use
were available at baseline in 478 patients (four missing;
Fig. 1). After the Dutch BOA Study, data on drug use and
outcome events were collected during a mean period of 20
months (range, 0e73 months) and were available in 388
patients (62 deaths and 32 missing). At the long-term
follow-up of the Dutch BOA Study, data on drug use and
outcome events were collected during a mean period of 29
months (range, 0e64 months) and available in 209 patients
(259 deaths and 14 missing).
Anti-thrombotic drugs
The percentages of anti-thrombotic, anti-hypertensive and
lipid-lowering drugs over the past decade are summarised inFig. 2. At baseline, 54% of patients received anti-thrombotic
drugs. Overall, most patients used anti-platelets (37%), 15%
used oral anticoagulants and 2% used both. The retrospec-
tively recorded anti-thrombotic drug use among patients
with venous and non-venous grafts is shown in Fig. 3. Before
BOA randomisation, anti-platelets were used more than oral
anticoagulants in both graft types.
Up to 2 years after the Dutch BOA Study, in which
patients were randomised between two anti-thrombotics,
evidently the total anti-thrombotic drug use had increased
to 94% (Fig. 2). Anti-platelets were used in 53% of patients,
oral anticoagulants in 43% of patients and both in 1%. The
use of oral anticoagulants more than doubled in both non-
venous and venous grafts (Fig. 3).
At the long-term follow-up of the Dutch BOA Study, the
total anti-thrombotic drug use remained stable at 96%
(Fig. 2). The use of anti-platelets increased further to 65%,
whereas fewer patients used oral anticoagulants (32%). The
use of both anti-thrombotics remained 1%. In all graft
types, the use of anti-platelets increased, while the use of
oral anticoagulants decreased in all graft types (Fig. 3).
Anti-hypertensive drugs
At baseline in the Dutch BOA Study, 49% of patients
received anti-hypertensive drugs (Table 1 and Fig. 2). Most
patients used diuretics (22%) and calcium channel blockers
(22%), followed by beta-blockers (20%) and angiotensin-I-
converting enzyme (ACE) inhibitors (19%; Fig. 4). Dual
therapy was applied in 27% of patients and consisted mostly
of diuretics with ACE-inhibitors (9%), followed by diuretics
with calcium channel blockers (8%).
After BOA, the use of anti-hypertensive drugs increased
to 64% (Fig. 4). The preference in type of anti-hypertensive
drug remained the same as before BOA randomisation. The
use of dual therapy increased to 35%. At long-term follow-
up, the use of anti-hypertensive drugs increased further to
76%. Currently, beta-blockers are used the most (40%),
followed by ACE-inhibitors (35%), diuretics (30%) and
calcium channel blockers (26%). Dual therapy is present in
45% of patients. Beta-blockers combined with ACE-inhibi-
tors were applied the most in 15%, followed by diuretics
with ACE-inhibitors in 13%.
Lipid-lowering drugs
At baseline of the Dutch BOA Study, 15% of patients used
lipid-lowering drugs (Table 1 and Fig. 2). Statins were
prescribed in almost all cases (Fig. 4). After the Dutch BOA
Study, the use of lipid-lowering drugs more than doubled to
40%. At long-term follow-up, lipid-lowering drug use (sta-
tins in almost all patients) increased further to 65% (Fig. 4).
Dual therapy of statins with fibrates stayed below 2% before
BOA, after BOA and at long-term follow-up.
Outcome events
Between the drug-use registration after BOA close-out until
the drug-use registration in patients still alive between
2005 and 2009, 68% of patients (126/388) experienced at
least one outcome event. Of all patients, who experienced
an outcome event, the majority of events occurred in
patients without a specific or any secondary drug treat-
ment, except for those treated with anti-hypertensive
drugs (Fig. 5).
Table 1 Patient characteristics of the Dutch BOA Follow-up Study at time of each data collection.
Before BOA:
1991e1995 N Z 478
Dutch BOA study:
1995e1998 N Z 482
After BOA:
1998e2000 N Z 388
Long-term follow-up of
BOA: 2005e2009 N Z 209
Patient characteristics N (%) N (%) N (%) N (%)
Demographic facts
Mean age 68 (SDa  10) 69 (SDa  10) 71 (SDa  10) 74 (SDa  10)
Male gender 311 (65) 313 (65) 254 (66) 136 (65)
Medical history
Smoking 287 (60) 289 (60) 238 (61) 135 (65)
Hypertension 184 (39) 186 (39) 145 (37) 71 (34)
Diabetes mellitus 109 (23) 109 (23) 84 (22) 37 (18)
Hyperlipaedemia 100 (20) 101 (21) 86 (22) 59 (28)
Angina pectoris 80 (17) 80 (17) 64 (17) 32 (15)
Myocardial infarction 75 (16) 75 (16) 57 (15) 29 (14)
TIAb and/or stroke 48 (10) 49 (10) 38 (10) 17 (8)
Vascular intervention 212 (44) 213 (44) 169 (44) 79 (38)
Peripheral arterial disease
Critical limb ischaemia 217 (45) 220 (46) 156 (40) 66 (32)
Type of trial graft
Femoro-popliteal 373 (78) 375 (78) 314 (81) 176 (84)
DAeBKc 169 (35) 170 (35) 139 (36) 74 (35)
Femoro-crural 105 (22) 107 (22) 74 (19) 33 (16)
Vein 311 (65) 313 (65) 245 (63) 133 (64)
In situ 75 (16) 76 (16) 59 (15) 32 (15)
Reversed 229 (48) 230 (48) 181 (47) 99 (47)
Other 7 (2) 7 (2) 5 (1) 2 (1)
Biograft 38 (8) 38 (8) 31 (8) 38 (8)
Prosthetic 129 (27) 131 (27) 112 (29) 59 (28)
PTFEd 54 (11) 55 (11) 46 (12) 25 (12)
Dacron 61 (13) 62 (13) 55 (14) 30 (14)
Combined 14 (3) 14 (3) 11 (3) 4 (2)
Allocated trial medication (1995e1998)
Oral anticoagulants 237 (50%) 239 (50%) 194 (50%) 97 (46%)
Before BOA: 478 patients,4 missings; After the Dutch BOA Study: 388 patients, 62 deaths, 32 missings; Long-term follow-up of the Dutch
BOA Study: 209 patients, 259 deaths, 14 missings.
a SD, standard deviation.
b TIA, transient ischaemic attack.
c DAeBK, distal anastomosis below the knee.
d PTFE, polytetrafluoroethylene.
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between 2005 and 2009 until the date of last follow-up or
death, 30% of patients (62/209) experienced at least one
outcome event. At long-term follow-up, a comparable
distribution of experienced outcome events among various
secondarymedical therapies was seen as after BOA close-out
(Fig. 5). However, the proportion of experienced outcome
events seemed to have halved.
Unfortunately, at follow-up, the number of experienced
outcome events were too small to show reliable percent-
ages of drug use per type of event, let alone per type of
bypass graft. Especially, the number of bypass occlusions at
follow-up were small, as most bypass occlusions occurred in
the first 2 years after surgery during the Dutch BOA Study,
the results of which have been published elsewhere.4Yet, enough data were available to evaluate the changes
in anti-thrombotic therapy from trial randomisation to
current anti-thrombotic drug use in patients, who had
previously experienced a bypass occlusion (Fig. 6). After
occlusion of a venous bypass, the use of anti-platelets
decreased linearly, while the use of anti-coagulants
increased linearly over time. In patients with a non-venous
bypass, no linearity was seen in changes of anti-thrombotic
drug use.
Discussion
We evaluated medical treatment over the past decade in
a sample of patients from the Dutch BOA Study. Only half of
patients with PAD used anti-thrombotics before they
Figure 2 Secondary prevention drug use over time. LD,
lowering drugs; FU, follow-up; Before BOA, time period up to
four years before start of the Dutch BOA Study in 1995; After
BOA, time period up to two years after close-out of the Dutch
BOA Study in 1998; BOA FU, time period from 2005 until 2009.
Medical Treatment after Peripheral Bypass Surgery 809underwent infrainguinal bypass surgery and were enrolled
in the Dutch BOA Study. It was not surprising that after the
Dutch BOA Study, in which patients were randomised
between oral anticoagulants and aspirin, nearly all patientsFigure 3 Anti-thrombotic drug use over time per graft material.
FU, follow-up; Before BOA, time period up to four years before star
two years after close-out of the Dutch BOA Study in 1998; BOA FU
Figure 4 Lipid-lowering and blood pressure-lowering drug use ove
enzyme; AT2, angiotensine II receptor; selective a1 receptor inhib
before start of the Dutch BOA Study in 1995; After BOA, time period
BOA FU, time period from 2005 until 2009.(94%) still used anti-thrombotics. Further, at long-term
follow-up, the use of anti-thrombotic drugs remained high.
The percentages of anti-hypertensive and lipid-lowering
drug use were low before the Dutch BOA Study, especially
for lipid-lowering drugs, but increased over time. However,
at long-term follow-up, the use of anti-hypertensive and
lipid-lowering drugs remained far from optimal. Currently,
only two-thirds of patients or less use statins, beta-blockers
or ACE-inhibitors, despite abundant evidence that these
treatments are beneficial for secondary prevention in
patients with PAD.8,9,11,12 This was largely supported by our
finding that less outcome events occurred in patients, who
received secondary medical prevention.
Anti-thrombotic drugs
Anti-thrombotic treatment of patients with PAD after
infrainguinal bypass surgery has proven highly beneficial for
bypass patency. Aspirin lowers the risk of bypass occlusion
by about 40% in the first year after surgery (odds ratio, 0.6;
95% confidence interval (CI), 0.5e0.8).13 Oral anticoagu-
lants reduce the odds of bypass occlusion by 23e30% within
1e2 years after surgery.14 Previous studies suggested and
the Dutch BOA Study confirmed that aspirin is especiallyOAC, oral anticoagulants; PAI, platelet aggregation inhibitors;
t of the Dutch BOA Study in 1995; After BOA, time period up to
, time period from 2005 until 2009.
r time. FU, follow-up; Ca, calcium; ACE, angiotensin converting
itor sympathicolytic; Before BOA, time period up to four years
up to two years after close-out of the Dutch BOA Study in 1998;
Figure 5 Outcome events per secondary medical prevention therapy. After BOA: time period up to two years after close-out of
the Dutch BOA Study in 1998; BOA FU: time period from 2005 until 2009; FU, follow-up; OAC, oral anticoagulants; PAI, platelet
aggregation inhibitors.
Figure 6 Changes in anti-thrombotic therapy after bypass
occlusion per graft material. Trial medication: the allocated
anti-thrombotic drug at inclusion in the Dutch BOA Study of
patients who experienced a bypass occlusion during the Dutch
BOA Study and up to the next drug use registration at two years
after BOA close-out; After BOA: anti-thrombotic drug use
registered within to two years after close-out of the Dutch BOA
Study in 1998 in patients who previously experienced a bypass
occlusion; BOA FU: anti-thrombotic drug use registered from
2005 until 2009 in patients who previously experienced
a bypass occlusion; FU, follow-up; OAC, oral anticoagulants;
PAI, platelet aggregation inhibitors.
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anticoagulants for the patency of venous grafts.4,1517
However, implementation of BOA recommendations after
study completion was unclear. We found that anti-platelets
were applied the most in both graft types. Further, the use
of oral anticoagulants had increased considerably in both
venous and non-venous grafts. For the latter conduit, this
was unexpected because the Dutch BOA Study had just
shown aspirin to prolong the patency of non-venous grafts
(hazard ratio (HR), 1.4; 95% CI, 1.0e1.6) more effectively
than that of venous grafts (HR, 0.7; 95% CI, 0.5e0.9).4 In
addition, oral anticoagulants were associated with
a twofold higher bleeding risk (HR, 1.9; 95% CI, 1.4e2.7)4
and generally are less favourable because of the need formonitoring INR and for frequent dose adjustments. Thus,
there is no clear rationale to treat patients who recently
received a non-venous graft with oral anticoagulants. A
possible explanation for this finding could be that, despite
the published results of the Dutch BOA Study, the allocated
trial medication was simply left unchanged as long as no
adverse events occurred. Another explanation could be
that treatment with oral anticoagulants was started in
patients after occlusion of non-venous grafts to improve
primary assisted or secondary patency, a frequent clinical
scenario.18 The latter, however, was not supported by our
finding of an increased use of anticoagulants after bypass
occlusion in patients with a venous bypass, but does affirm
our prior suggestion that trial medication was only
adjusted, according to BOA recommendations, after the
occurrence of an adverse event.
Both anti-platelets and oral anticoagulants largely
reduce the risk of myocardial infarction, stroke and
vascular death.4,10,19 This beneficial effect was confirmed
by the lower number of outcome events observed in
patients with anti-thrombotic therapy compared with those
without. Unfortunately, the number of outcome events that
occurred at follow-up was too small to allow for a reliable
evaluation per event. In the Dutch BOA Study, a favourable
trend was seen for oral anticoagulants versus aspirin in
reducing the risk of vascular death, non-fatal myocardial
infarction, non-fatal stroke or amputation (HR 0.9; 95% CI,
0.8e1.1).4 However, the risk of bleeding, including hae-
morrhagic strokes, increased twofold with oral anticoagu-
lants compared with aspirin (HR, 1.9; 95% CI, 1.4e2.7). The
combined treatment of aspirin with oral anticoagulants was
found to be not more efficient than aspirin alone in the
prevention of ischaemic events.19,20 Moreover, bleeding
complications occurred two to three times more frequently
with dual anti-thrombotic treatment compared with aspirin
alone. Therefore, most guidelines favour the use of aspirin
alone over oral anticoagulants.1,21 The eighth edition of
Medical Treatment after Peripheral Bypass Surgery 811American College of Chest Physicians (ACCP) Evidence
Based Clinical Practice Guidelines recommend oral antico-
agulants plus aspirin only in patients at high risk of bypass
occlusion or limb loss without specifying the risk factors.21
The PAD Antiplatelet Consensus Group and the Trans-
Atlantic Inter-Society Consensus II (TASC II) both suggest to
only use oral anticoagulants in patients with a venous graft
after an individual evaluation, without explaining how to
evaluate this.
Anti-hypertensive and lipid-lowering drugs
Anti-hypertensive drugs are recommended to reduce the
risk of myocardial infarction, stroke and cardiovascular
death in PAD patients with or without hypertension.2225 In
the Heart Outcomes Prevention Evaluation (HOPE) trial, the
use of ramipril significantly reduced the risk of myocardial
infarction (absolute risk reduction (ARR), 3.8%; relative risk
(RR), 0.8%, 95%CI 0.7e0.9), stroke (ARR, 1.5%; RR, 0.7%,
95%CI 0.6e0.8) and cardiovascular death (ARR, 2.0%; RR,
0.7%, 95%CI 0.6e0.9) in high-risk patients.8 Besides ram-
ipril, other ACE-inhibitors and also beta-blockers decreased
the risk of mortality in patients with PAD.11 Previously, the
use of beta-blockers has been discouraged in patients with
PAD because beta1-receptor blockade decreases cardiac
output and induces relaxation of smooth muscle in blood
vessels, which was presumed to worsen claudication
symptoms. However, beta-blockers do not seem to worsen
PAD symptoms and are indicated in the absence of
contraindications such as asthma, chronic obstructive
pulmonary disease or an atrioventricular block.22,23,26
Alternative anti-hypertensive agents are calcium antago-
nists, diuretics and angiotensin-II receptor antagonists, but
large controlled trials that address their effect in PAD
patients are lacking.22,23 In accordance with the evidence-
based recommendations, beta-blockers and ACE-inhibitors
were used the most in our patients, but, still, a third of
patients did not receive any anti-hypertensive drug for
secondary prevention. However, the beneficial effect of
anti-hypertensive medical treatment could not be observed
in our findings. Perhaps, this beneficial effect of beta-
blockers and ACE-inhibitors is blurred by the substantial use
of other anti-hypertensives in our study, such as diuretics
and calcium antagonists, whose protective effects in PAD
patients are still unclear. Again, the number of outcome
events that occurred at follow-up was too small to allow for
reliable evaluations per type of anti-hypertensive drug.
Statins are indicated for all patients with PAD, whether
they are symptomatic or asymptomatic, and irrespective of
the low-density lipoprotein (LDL) cholesterol level, as sta-
tins significantly reduce the risk of cardiovascular events
and death in each condition.1,9,12,27 This was supported by
our lower number of outcome events observed in patients
with lipid-lowering therapy compared with those without.
Still, one-third of our patients was deprived of statin
therapy.
Undertreatment
Previously, it was recognised that patients with PAD, who
underwent peripheral bypass surgery, often do not receiveoptimal secondary medical prevention. Multiple studies
reported anti-thrombotic, anti-hypertensive and statin
treatments, recorded between 1993 and 2006, to be below
40% to as low as 12%.2831 Over time, little to no improve-
ment in the reported treatment percentages was seen,
despite the fact that the clinical evidence on secondary
medical prevention in PAD patients, referred to by inter-
national guidelines,13 piled up in the past 30 years.
Already, in 1983, Duffield et al. demonstrated the benefi-
cial effects of lowering plasma lipids in patients with PAD;
this was followed by the Cholesterol Lowering Atheroscle-
rosis Study (CLAS)32 in 1991, the Probucol Quantitative
Regression Swedish Trial (PQRST)33 in 1994 and the Heart
Protection Study Group in 2002.9 Kretschmer et al. reported
an increased survival in patients treated with oral antico-
agulants in 198834 and the Antiplatelet Trialists’ Collabo-
rationfor treatment with anti-platelets in 1994.35 Reports
on the beneficial effects of certain anti-hypertensive drugs
appeared in the late 1990s.8,26
With this abundant amount of high-level evidence, one
would expect less undertreatment nowadays. Already in
2002, the Secretary General of the European Society for
Vascular Surgery (ESVS) emphasised that patients with PAD
require a multidisciplinary approach regarding risk factor
reduction and secondary medical prophylaxis.36 He
summoned vascular surgeons to take responsibility for their
patients’ total care and proposed an education programme
to update the vascular surgeons’ knowledge on secondary
medical prevention. In our opinion, not only the vascular
surgeon has the responsibility to keep up with new
evidence on atherosclerotic risk management, but also the
general practitioner (GP). Because atherosclerosis has
a high incidence and prevalence and most patients are
asymptomatic,1 the GP is able to detect high-risk patients
earlier and prevent more adverse events than specialists,
who usually treat symptomatic patients at a more advanced
stage of their disease. Perhaps a standardised ESVS protocol
with flowcharts for decision making on anti-thrombotic
treatment and additional medical prevention and risk
management strategies will facilitate vascular surgeons and
other physicians to apply the correct and complete
secondary prevention treatment in patients with PAD. To
introduce and sustain a complete vascular prevention pro-
gramme in clinical practice, a patients’ routine visit to the
vascular clinic is believed necessary. In addition, these
repetitive visits might augment a patients’ compliance to
new lifestyle modifications and medical treatment. To
facilitate the increased workload, the aid of a physician
assistant or nurse practitioner is mandatory for patient
counselling, performing additional testing, maintaining an
overview of the secondary prevention applied per patient
and preventing inadequate care.
Strengths and limitations
This study provides an extensive overview on drug use in
patients with PAD over more than a decade. To our
knowledge, this has not been described over such a time
period before. A study limitation was the partly retro-
spective data collection having an increased risk of missing
data and lacking accurate information on the reason for
812 E.S. van Hattum et al.starting, discontinuing or switching certain medical treat-
ments over time. However, the drug use at long-term
follow-up for patients still alive between 2005 and 2009 was
collected prospectively, including patient baseline charac-
teristics at BOA inclusion. Other limitations, which are
inherent to an observational study, were the possibility of
selection bias and survival bias. Patients from the six
centres that included the most patients in the Dutch BOA
Study were selected for our follow-up study for methodo-
logical and logistic reasons. Limiting the number of centres
augmented the feasibility of a thorough data collection and
allowed a more standardised applied surgical technique and
postoperative and outpatient follow-up policy, minimising
their effect on the long-term outcome of PAD patients.
Furthermore, patients still alive at the long-term follow-up
of the Dutch BOA Study are most likely to have a relatively
lower cardiovascular risk, and perhaps received better
secondary medical prevention compared with those
deceased. Survival bias probably explains the observed
lower percentages of outcome events at long-term follow-
up. Therefore, the reported percentages of drug use might
be overestimated and should be interpreted with appro-
priate caution.
Conclusion
This study was the first to describe the change in drug
treatments in PAD patients over 10 years after peripheral
bypass surgery. Implementation of anti-thrombotic therapy
after peripheral bypass surgery recommended on the basis
of the Dutch BOA trial in the same study population was
marginal, and did not seem to adhere to international
guidelines either. Although secondary medical prevention
improved over time, the anti-hypertensive drug and
statin use also remained far from optimal. There is a strong
need for further improvement of applied anti-thrombotic
and other secondary medical therapy, shortly after
peripheral bypass surgery and at long-term follow-up in PAD
patients.
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